1. How to use GuruFocus - Tutorials
  2. What Is in the GuruFocus Premium Membership?
  3. A DIY Guide on How to Invest Using Guru Strategies
James Li
James Li
Articles (638)  | Author's Website |

Stanley Druckenmiller Starts 3 Positions in 3rd Quarter

Guru reports quarterly portfolio

November 15, 2017 | About:

Stanley Druckenmiller (Trades, Portfolio), former partner of George Soros (Trades, Portfolio)’s Quantum Fund, initiated three positions during the third quarter: Citigroup Inc. (NYSE:C), Chubb Ltd. (NYSE:CB) and Celgene Corp. (NASDAQ:CELG).


The Duquesne Capital fund manager invested in 1,095,200 shares of Citigroup for an average price of $68.28 per share. With this transaction, Druckenmiller expanded his portfolio 3.62%.


Citigroup’s profitability ranks 4 out of 10, suggesting modest growth potential. The company’s margins and returns are near a 10-year high yet underperform over 55% of global competitors.



Citigroup has a negative three-year compound annual growth rate (CAGR) of sales, a severe warning sign according to GuruFocus. The company’s revenues in Corporate / Other declined 55% primarily due to the “continued wind-down of legacy non-core assets.” Despite this, overall company revenues increased 2% year over year.



Druckenmiller added 206,600 shares of Chubb for an average price of $144.66 per share. With this transaction, the guru increased his portfolio 1.34%.


Chubb’s profitability rank of 5 suggests the company has satisfactory growth potential. The company said in its third-quarter report that although revenues increased 1% from the prior-year quarter, it still reported a net loss of $70 million due to a $1.893 billion pretax catastrophe loss as a result of the three hurricanes and other natural disasters.



Druckenmiller added 188,100 shares of Celgene for an average price of $135.96 per share. With this transaction, the fund manager increased his portfolio 1.25%.


Celgene’s profitability rank of 9 suggests strong short-term growth potential. The company reported net product sales of $3.283 billion for the quarter, up 11% from the prior-year quarter. The strong increase in product sales contributed to a three-year revenue growth of 22.80%, which outperforms 76% of global biotech companies.


Disclosure: I do not have positions in the stocks mentioned.

About the author:

James Li
I am an editorial assistant and researcher at GuruFocus. I have a Master's in Finance from SMU, and I enjoy writing reports on financial trends and investor portfolios. Follow me on Twitter at @JamesLiGuru!

Visit James Li's Website

Rating: 0.0/5 (0 votes)


Please leave your comment:

Performances of the stocks mentioned by James Li

User Generated Screeners

bjwrightLow debt
kislevamnonSSUPECT-TOO bad
pbarker46Insider cluster buying
kislevamnonjames montier
kislevamnonhigh quality
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat